1、 2015 10 2017 8 148 , (74 ) (74 ) , , 10 m L 250 m L, 1 /d 2 , -1 (ET-1) N- (NT-pro BNP) - - 6 min (6MWT) , 79.73%, 93.24%, (P0.05) , (LVESD) (LVEDD) , (CI) (LVEF) , (P0.05) ; , (P0.05) , ET-1 NT-pro BNP TNF- , 6MWT , (P0.05) ; 6MWT , (P0.05) , , ; ; ; ; N- ; ; (1980 ) , , , Tel:13772572380E-mail: (
2、1979 ) , , , E-mail: Clinical study on Sofren Injection combined with recombinant human brain natriuretic peptide in treatment of congestive heart failure NING Xiao-kang WANG Wen-li WU Xiang-yang CHENG Yan Department of Cardiology, Affiliated Hospital of Shaanxi University of Traditional Chinese Med
3、icine; Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine; Xian Yanta District Traditional Chinese Medicine Hospital; Abstract Objective To explore the clinical effect of Sofren Injection combined with recombinant human brain natriuretic peptide in treatment of congestive hear
4、t failure. Methods Patients (148 cases) with congestive heart failure in the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from October 2015 to August 2017 were randomly divided into control (74 cases) and treatment (74 cases) groups. Patients in the control group were iv
5、 administered with Recombinant Human Brain Natriuretic Peptide for injection, the first dose of intravenous pulse treatment group were iv administered with Sofren Injection on the basis of the control group, 10 m L added into normal saline 250 m L, once daily. Patients in two groups were treated for
6、 2 weeks. After treatment, the clinical efficacy was evaluated, echocardiographic indexes, ET-1, NT-pro BNP, TNF-compared. Results After treatment, clinical efficacy in the control group was 79.73%, which were significantly lower than 93.24% in the treatment group, and there were differences between
7、 two groups (P 0.05) . After treatment, the LVESD and LVEDD in two groups were significantly decreased, but the CI and LVEF was significantly increased, and the difference was statistically significant in the same group (P 0.05) . And the improvement of echocardiographic indexes in the treatment gro
8、up was significantly better than that in the control group, with significant difference between two groups (P 0.05) . After treatment, the ET-1, NT-pro BNP, and TNF- 6 MWT was significantly increased, there were differences in the same group (P 0.05) . And these serum markers levels and 6 MWT in the
9、 treatment group were significantly better than those in the control group, with significant difference between two groups (P 0.05) . Conclusion Sofren Injection combined with recombinant human brain natriuretic peptide can significantly relieve heart failure symptoms and improve the cardiac functio
10、n in treatment of congestive heart failure, which has a certain clinical application value. Keyword Sofren Injection; Recombinant Human Brain Natriuretic Peptide for injection; congestive heart failure; LVESD; NT-pro BNP; LVEF; , , , 1 DNA , 2 , , , , 3 1 1.1 2015 10 2017 8 148 , : 4 86 , 62 , 4580
11、, ; 110 , ; 85 , 53 , 10 1.2 : ; (NYHA) ; , ; ; 4080 ; , 1.3 ;3 , / mm Hg=133Pa) ; ; ; ; ; ; , ; 1.4 , 0.5 mg/500 U/ , 150812; , 5 m L/ , 150922 1.5 148 (74 ) (74 ) , 44 , 30 ; 4579 , ; 19 , ; 42 , 28 , 4 42 , 32 ; 4580 , 2) ; 110 , ; 43 , 25 , 6 , , , , 10 m L 250 m L, 1 /d 2 1.6 5 : , 2 ; : , 1 ;
12、: 1.7 1.7.1 , (LVESD) (LVEDD) (CI) LVEF 1.7.2 , , -1 (ET-1) , (ELISA) N- (NT-pro BNP) - - 1.7.3 6 min (6MWT) 6MWT 1.8 1.9 SPSS 17.0 , t , 2 2.1 , 27 , 32 , 15 , 79.73%; 34 , 35 , 5 , 93.24%, (P0.05) , 1 2.2 , LVESD LVEDD , CI LVEF , (P0.05) ; , (P0.05) , 2 2.3 ET-1 BNP TNF- 6MWT , ET-1 NT-pro BNP TN
13、F- , 6MWT , (P0.05) ; 6MWT , (P0.05) , 3 1 Table 1 Comparison on clinical efficacies between two groups 2 3 ET-1 BNP TNF- 6MWT on ET-1, BNP, TNF- 2.4 , 1 , 3 , , (SNS) (RAAS) 6 , , , BNP , DNA , BNP , 7 , , , , , , , LVEF , 8 9 , BNP , NT-pro BNP BNP , BNP , NT-pro BNP , , , , 10 , NT-pro BNP, , NT-
14、pro BNP , 11 , NT-pro BNP , NT-pro BNP , , , , , , , , 12 , , , , , , , , , , , , , H , 13 , , , , , , , 14 , , , , , , , , , , , , 15 , , , , , 16 , NT-pro BNP , NT-pro BNP , NT-pro BNP , ET-1 , , , , ET-1 , , , , BNP , , 17 , ET-1 , , ET-1 , , , TNF- , TNF- , , , , , 6MWT , , , , , , , 1 , . J. ,
15、2013, 22 (2) :192-193. 2 , , . J. , 2014, 43 (24) :2922-2924. 3 , , , . J. , 2016, 43 (10) :2138-2140. 4 : M. : , 2009:5-10. 5 . ( ) M. : , 2002:79. 6 , , , . J. , 2015, 21 (4) :577-579. 7 , . J. , 2016, 27 (35) :4977-4979. 8 , , , . -6 J. : , 2014, 35 (1) :98-100. 9 , . J. , 2014, 29 (6) :648-651. 10 .NT-pro BNP J. , 2016, 25 (4) :402-404. 11 , , , .NT-pro BNP NYHA LVEF J. , 2
